Administration of exogenous IL-18 to these mice aggravated disease activity and nephritis, and IL-18-deficient mice or mice treated with anti-IL-18 in the MRL/lpr model showed improved survival rates and reduction of proteinuria [13, 37–39]. The gene discussed is IL18; the disease is nephritis.